CG Oncology, Inc. (CGON)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, CG Oncology, Inc. reported revenue of $4.04M, up 254.7% from the prior year. The company ran a net loss, with a net margin of -3985.0%. It held $791.59M in total assets against $38.99M in total liabilities.
Key ratios (FY2025)
-4722.1%
Operating margin
-3985.0%
Net margin
-21.4%
Return on equity
+254.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.04M | $1.14M | $204.0K | — |
| Operating Income | -$190.77M | -$114.67M | -$55.45M | — |
| Net Income | -$161.00M | -$88.04M | -$48.61M | — |
| EPS (Diluted) | $-2.08 | $-1.41 | $-15.65 | — |
| Total Assets | $791.59M | $754.80M | $199.30M | — |
| Total Liabilities | $38.99M | $21.42M | $14.51M | — |
| Shareholders' Equity | $752.60M | $733.38M | -$123.10M | -$77.69M |
| Cash & Equivalents | $32.49M | $257.07M | $8.27M | — |
| Operating Cash Flow | -$132.35M | -$78.71M | -$45.68M | — |
| Capital Expenditures | $134.0K | $234.0K | — | — |
| Shares Outstanding | 80.69M | 76.15M | 5.22M | — |